EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The Impact of Pazopanib on the Cardiovascular System

Cody N Justice iD, Mohamed H Derbala, Tesla M Baich, Amber N Kempton, Aaron S Guo, Thai H Ho, Sakima A Smith

Journal of Cardiovascular Pharmacology and Therapeutics · 2018-09 · 23 (5) · 387-398

DOI: 10.1177/1074248418769612 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, online erschienen am 29.04.2018. Verfasst von Cody N Justice und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1 Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its cardiovascular side effects. Pazopanib and other vascular endothelial growth factor receptor tyrosine kinase inhibitors have been associated with the development of hypertension, QT interval prolongation, and other cardiovascular events; however, these mechanisms are largely unknown. Gaining a deeper understanding of these mechanisms is essential for the development of appropriate surveillance strategies and possible diagnostic biomarkers to allow us to monitor patients and modulate therapy prior to significant cardiac insult. This approach will be vital in keeping patients on these life-saving therapies and may be applicable to other tyrosine kinase inhibitors as well. In this review, we provide a comprehensive overview of the preclinical and clinical side effects of pazopanib with a focus on the mechanisms responsible for its toxicity to the cardiovascular system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsAnimalsCarcinoma, Renal CellCardiovascular DiseasesCardiovascular SystemHumansIndazolesKidney NeoplasmsPyrimidinesRisk AssessmentRisk FactorsSarcomaSoft Tissue NeoplasmsSulfonamidesTreatment Outcome

Stichwörter der Autor:innen

hypertensionpazopanibrenal cell carcinomatyrosine kinase inhibitors

Substanzen

Angiogenesis InhibitorsIndazolesPyrimidinesSulfonamidespazopanib

Autor:innen und Institutionen

  • 1 Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA.
  • 2 Mayo Clinic Scottsdale, Arizona, Phoenix, AZ, USA.
  • 3 Division of Cardiology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.

ORCID-Profile: Cody N Justice

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Justice, C. N., Derbala, M. H., Baich, T. M., Kempton, A. N., Guo, A. S., Ho, T. H., & Smith, S. A. (2018). The Impact of Pazopanib on the Cardiovascular System. Journal of Cardiovascular Pharmacology and Therapeutics, 23(5), 387-398. https://doi.org/10.1177/1074248418769612

Vancouver

Justice CN, Derbala MH, Baich TM, Kempton AN, Guo AS, Ho TH, et al. The Impact of Pazopanib on the Cardiovascular System. Journal of Cardiovascular Pharmacology and Therapeutics. 2018;23(5):387-398. doi:10.1177/1074248418769612

BibTeX
@article{Justice2018,
  author = {Justice, Cody N and Derbala, Mohamed H and Baich, Tesla M and Kempton, Amber N and Guo, Aaron S and Ho, Thai H and Smith, Sakima A},
  title = {The Impact of Pazopanib on the Cardiovascular System},
  journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
  year = {2018},
  volume = {23},
  number = {5},
  pages = {387--398},
  doi = {10.1177/1074248418769612}
}
Kostenlos starten →